Certain pancreatic tumours often employ autophagy to overcome inhibition of the RAF-MEK-ERK signaling pathway https://www.nature.com/articles/s41591-019-0367-9
But if you combine an autophagy inhibitor, such as hydroxychloroquine with a MEKi and/or RAFi, there seems to be some promising data https://www.nature.com/articles/s41591-019-0368-8
In this paper, it was shown that inhibition of autophagy enhanced sensitivity to dual immune checkpoint inhibition (anti-CTLA-4 plus anti-PD-1) https://www.nature.com/articles/s41586-020-2229-5
As most patients don't respond to either anti-CTLA-4 or anti-PD-1, it might make sense to only use all three if you are dMMR https://science.sciencemag.org/content/357/6349/409